The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Evidence is building that overall survival (OS) among patients with advanced non-squamous non–small cell lung cancer (NSCLC) is prolonged by pembrolizumab plus pemetrexed and carboplatin compared with pemetrexed and carboplatin alone, according to a study presented at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer (WCLC) in Japan.1

In the phase 1/2 KEYNOTE-021 study (ClinicalTrials.gov Identifier: NCT02039674), researchers randomly assigned 123 patients with NSCLC to receive pemetrexed and carboplatin with or without pembrolizumab as first-line therapy. Initial analysis of cohort G at a median of 10.6 months showed that pembrolizumab significantly improved overall response rate (ORR) and progression-free survival (PFS).

The median follow-up was 18.7 months for this analysis. Patients who received pembrolizumab plus pemetrexed and carboplatin had an ORR of 57% vs 32% among patients who did not receive pembrolizumab (estimated difference 25%; 95% CI, 7%-41%; P = .0029). PFS was significantly prolonged for patients who received pembrolizumab, with a median of 19.0 months (95% CI, 8.5-not reached [NR]), vs 8.9 months (95% CI, 6.2-11.8) for patients who received pemetrexed and carboplatin alone (HR, 0.54; 95% CI, 0.33-0.88; P = .0067).

Related Articles

Patients who received pembrolizumab plus pemetrexed and carboplatin did not reach a median OS (95% CI, 22.8-NR) compared with 20.9 months (95% CI, 14.9-NR) among patients who received pemetrexed and carboplatin alone (HR, 0.59; 95% CI, 0.34-1.05; P = .0344).

Grade 3 to 5 adverse events were reported by 41% of patients who received pembrolizumab compared with 29% who received pemetrexed and carboplatin alone.

Read more of Cancer Therapy Advisor‘s coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.

Reference

  1. Borghaei H, Langer CJ, Gadgeel SM, et al. Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC: KEYNOTE-021 cohort G update. Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; October 2017; Yokohama, Japan. Abstract OA 17.01.